Ultrasound vendor Biosound of Indianapolis will unveil a majorproduct upgrade developed by its parent, Esaote Biomedica of Italy.Introduced as an upgrade for Biosound's high-performance AU4 platform,Advanced Contrast Technology (ACT) incorporates
Ultrasound vendor Biosound of Indianapolis will unveil a majorproduct upgrade developed by its parent, Esaote Biomedica of Italy.Introduced as an upgrade for Biosound's high-performance AU4 platform,Advanced Contrast Technology (ACT) incorporates interactive managementof apodization and dynamic control of beam amplitude to improvecontrast resolution. ACT also provides time-wait processing thatadapts the beam velocity to different tissue impedances. An inexpensiveblack-and-white, color-upgradable version of Biosound's AU3 systemwill also be shown.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.